Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Latest news / GMiA calls on government to think before irreversible damage occurs to the generic medicines industry

GMiA calls on government to think before irreversible damage occurs to the generic medicines industry

March 13, 2014 By Emilia

13 March 2014.

Today, at the Annual Professional Pharmacy (APP) conference attended by members of the National Pharmacy Guild of Australia, Mr Mark Crotty, Chairman of the Generic Medicines Industry Association (GMiA), called on government to think before irreversible damage occurs to the generic medicines industry in Australia.

Mr Crotty highlighted, “PBS reform is delivering more savings than expected and to avoid inflicting irreversible damage to the generic medicines industry, it is important that there are no more damaging price cuts to generic medicines”.

These unforecasted and unplanned savings are most damaging to the generic medicines sector and disproportionately damage the generic medicines industry model placing at risk a viable generic medicines industry and patient access to medicines. Policy changes are urgently required.

It is imperative that if Australians want a best practice PBS, we should not aim for the ‘cheapest’ scheme or cherry-pick elements from other countries. A best practice PBS provides a stable industry with fair remuneration from the PBS and is an essential foundation for the entire medicines industry in Australia.

-Ends-

Filed Under: Latest news, News 2014

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton AO PSM, joins GBMA as its inaugural Independent … More...

Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists

December 8, 2020

12 November 2020 Canberra, ACT New research shows prescriber … More...

IGBA Launches First Global Biosimilars Week

December 7, 2020

16 November 2020 Geneva, Switzerland Today the International Generic and … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us